and MATSUMOTO, K. Combination Therapy o f Esophageal Carcinoma with Radiation and Bleomycin. Tohoku J. exp. Med., 1981, 134 (4), 417-424--The concurrent combination therapy of radiation and Bleomycin was performed in a total of 175 cases of esophageal carcinoma. In 107 (63%) cases of them, in which the scheduled curative treatment was completed, yearly survival rates were 60% in one, 30% in two, 20% in three and 7% in five years. The local recurrence was noted in 60% and remote metastases were observed in 38% of them. These results were intimately correlated to tumor advancement and cancer type. From the results, it was concluded that this combination therapy should be valuable to prolong the life of a cancer patient, improving one to three year survival rates, and that the curable indications for this treatment should be T1 MO and T2 MO with tumorous or some ulcerous types of carcinoma, radiation therapy; esophagea carcinoma; Bleomycin
Recently, combinations of radiation and surgery have improved the treatment results of esophageal carcinoma, while the indications for surgery are greatly limited by the advancement of tumor, the tumor location, complications at advanced age, etc. Radiation therapy is the one and only curative treatment for the cases in which esophagectomy is not indicated. But, the treatment results in radiation therapy of esophageal carcinoma are generally poor and five-year survival rate is less than 10%, because of dose limiting problems that will restrict the role of radiation therapy and specific characteristics of this carcinoma, such as the invasion of vital structures, diffuse infiltration of the submucosa, skip lesions and early lymph node metastases.
To augment the radiation effect on primary lesion and lymph node metastases within the irradiation field, we have been trying the concurrent combination therapy of radiation and Bleomycin for esophageal carcinoma. In this treatment, chemotherapeutic effect of Bleomycin alone may be also expected on the subclinical invasions and/or metastases in the outside of irradiation field.
In this study, to evaluate this combination therapy of esophageal carcinoma, yearly survival rates and the status of local recurrence and metastases are analyzed and discussed in relation to some clinical factors.
MATERIALS AND TREATMENT
During the ten-year period from 1969 to 1978, 175 cases of esophageal carcinoma were treated by the combination therapy with radiation and Bleomycin at Department of Radiology, Miyagi Seijinbyo Center. The histological diagnosis of esophageal cancer was confirmed by endoscopic biopsy in all cases, by which they were classed to 158 cases of squamous cell carcinoma, six of adenocarcinoma, six of anaplastic one and five of not specified carcinoma.
Fifty-two cases of them were classed to the palliative group and 123 to the curative one. The former group included 43 cases with remote metastases already before the initiation of this treatment, three cases concurrently complicated by advanced cancer of the stomach and six cases with apparent fistulation. They were made up of 44 males and 8 females in the age range from 48 to 80 years old (65.5 on the average).
The latter group comprised the other 123 cases of 102 males and 21 females in the age range from 45 to 83 years old (68.9 on the average). By TNM classification of malignant tumors (UICC, 1978), they were classified into seven cases (6%) of T1, 62 (50%) of T2 and 54 (44%) of T3, and by cancer type according to the "Descriptive Rules in Clinic and Pathology" (Japanese Society of Esophageal Disease), they were classified to 66 (54%) of spiral type, 27 (22%) of serrated, 16 (13%) of funnelled and the other 14 (11%) of tumorous one.
Six MV X-ray was used in radiation therapy. The dose fractionation was 200 rad/day, five times a week in 71 and 250 rad/day, four times a week in 104 cases. In the curative group, a tumor dose of 3000-4000 rad was given through two opposed portals for the first 3-4 weeks and if a cure could be expected, an additional dose of 3000-4000 rad was then irradiated by 240° rotation, and if it could not be expected, the two opposed irradiation was continued to a total dose of 6000 rad. In the palliative group, the two opposed irradiation technique was employed to a total dose of 5000 rad throughout all treatment period.
Bleomycin was combined concurrently with radiation at the first 3-4 weeks. Until the end of 1973, it had been given one hr after irradiation in various intravenous doses (30, 15 or 7.5 mg twice a week). Since 1974, an intramuscular dose of 5 mg was injected immediately before each irradiation, on the basis of new findings in radiobiological studies (Fukuda et al. 1976; Takabe and Terashima 1976) . The total dose of Bleomycin was 50 to 300 mg.
RESULTS

Treatment results in the palliative group
As shown in Table 1 , the treatment results in 52 cases of the palliative group were very poor, with one year survival of only six (12%) and none of two-year survival. The median survival period in this group was six months. According to the sites of metastases, one-year survival was achieved in two (13%) of 16 cases with remote lymph node metastases, two (14%) of 14 with lung metastases and two (18%) of 11 with liver metastases. The longest median survival period of seven months was obtained in the cases with remote lymph node metastases. One-year survival was achieved in none of the cases concurrently accompanied with advanced gastric carcinoma and none of those with apparent fistulation.
Treatment results in the curative group
Out of 123 cases in the curative group, the scheduled combination therapy with a total tumor dose of more than 5000 rad was completely performed in 107 cases. It was withdrawn in the other 16 cases from such reasons as aggravation of general condition (in seven cases), massive bleeding (in four cases), perforation of the esophagus (in four cases) and cerebral hemorrhage (in one case). All these 16 cases terminated fatally within three months after the withdrawal of the combination therapy.
As seen in Table 2 , the yearly survival rates in 107 cases were 60% in one year, 30% in two, 20% in three, 9% in four and 7% in five years. During the first three years, the T1 cases showed the most favorable results with one, two and three years survival rates of 100%, but there was no five years survival in them because of late remote metastases without any evidence of local recurrence and mortality from other diseases. Five-year survival was observed only in the T2 cases and this rate was 11%. The result was very poor in the T3 cases, with three-year survival of only 7%. The survival rates were intimately correlated to T classification (the clinical stage); the higher the stage, the poorer was the result.
As shown in Table 3 , the tumorous type cases showed rather favorable results with three-year survival of 40%, but there was no five -year survival because of late remote metastases. In the funnelled type cases, the results were the worst and there was no three-year survival. Out of the ulcerous type cases, yearly survival rates in the serrated type cases were better than those in the spiral type cases. Five-year survival was noted in both types, and the rate was 10% in the former and 9% in the latter. Furthermore, the prognostic X-ray findings TABLE 2. Survival rates in the curative group (T classification) of the carcinomatous ulcer with better prognosis were shallow in the depth of ulcer and smooth in its margin.
The survival rates in relation to the location of tumor were shown in Table 4 . In the cases with cancer lesion located in the upper thoracic esophagus (Iu), these rates were the lowest with one-year survival rate of 38% and none of two-year survival. In the cases with lesion located in the middle thoracic esophagus (Im), they were slightly better but five-year survival rate was only 3%. The best result was noted in the lower thoracic and abdominal esophagus (Ei+Ea) with five-year survival rate of 20%.
Recurrence and metastases in the curative group
Out of 107 cases, treated completely with this therapy, 19 cases have been alive and well in one to eight years after the completion of this treatment. Fatal termination has been confirmed in 88 cases and 77 of 88 ones were clinically followed up until the death, revealing the status of local recurrence and remote metastases. But, such status could not be traced in the other 11 cases.
Out of 77 cases, 66 died from local recurrence and/or remote metastases of esophageal carcinoma. The former was noted in 46 (60%) of 77 cases and the latter was done in 29 (38%) of them. Neither recurrence nor metastases was Survival rates in the curative group (the location of tumor found in the other 11 cases : five cases terminated fatally from the intercurrent diseases, such as uremia, heart failure, liver cirrhosis, radiation myelopathy and Bleomycin pneumonitis; six died from esophageal perforation after the completion of the treatment.
As shown in Table 5 , local recurrence was noted in none of the Ti cases, in 22 (55%) of the T2 and in 24 (72%) of the T3 ones. Thus, the higher the T, the more frequent was local recurrence. On the contrary, remote metastases were more frequent in the T1 and T2 cases than in the T3 ones. They were found in 2 (50%) of the Ti, in 17 (43%) of the T2 and in 10 (30%) of the T3 cases.
As seen in Table 6 , local recurrence was the most frequent in the funnelled type, with the recurrence rate of 88% and this rate was followed by the rate of 68% On the other hand, remote metastases were the most frequent in the tumorous type, occurring in 82%. They were observed in 41% of the serrated type and in 32% of the spiral type, but found in none of the funnelled type.
DISCUSSION
Radiobiological and clinical studies of concurrent combination therapy with radiation and Bleomycin have rapidly progressed in Japan. As a result of basic studies of this treatment, it was reported that because the injurious effect of Bleomycin on cancer cells differed from that of radiation, the concurrent combination of these two treatment modalities would exert a synergistic anticancer effect (Fukuda et al. 1976; Takabe and Terashima 1976) . Clinical studies of this combination therapy, by analysis of tumor regression curves in the cases of head and neck epidermoid carcinoma (Taketa et al. 1971 ) and in those of esophageal carcinoma (Asakawa et al. 1972) , showed that such treatment promoted the tumor regression speed. Ristologic studies in surgically extirpated materials of esophageal cancer also revealed that in the cases treated preoperatively with this combination, the cancer cells in the primary and metastatic lesions within the irradiation field were markedly damaged as compared with the damage of cancer cells in the cases treated with radiation alone, and that Bleomycin was slightly effective even on the lymph node metastases in the outside of the irradiation field (Tanaka 1973; Watanabe et al. 1974; watarai et al. 1975 ). So, it seems that the combination therapy with radiation and Bleomycin for esophageal carcinoma will presumably improve the clinical course of this malignancy. But, as there has been no report on long-term results of this concurrent combination therapy of esophageal carcinoma, the advantage, limitation and curability of this combination therapy will be discussed from the findings in our present study.
In many reports of radiotherapy of esophageal carcinoma in Japan and other countries (Abe et al. 1972; Becker and Fassbender 1970; Frazier et al. 1970; Hellriegel 1972; Kaneta et al. 1968; Kiyono et al. 1973; Koga 1968; Oshima et al. 1973; Saeki et al. 1973; Schmitt et al. 1971; Takaoka et al. 1968) , curative radiotherapy was defined to the irradiation of more than 4000 rad for the cases without any evidence of remote metastases, and in these reports, one-year survival rate was 30 to 40% and a cure rate was less than 10%. But, in a few reports (Mikuriya et al. 1976; Morita et al. 1974; Pearson 1977) , in which curative radiotherapy was performed for the selected cases except the far advanced ones, a cure was obtained in slightly higher rate of 10 to 20%. Our results in the curative group, including the far advanced cases, indicated such a high one-year survival rate as 60% and also slightly high two-and three-year survival, but a similar five-year survival rate. Moreover, an incidence of local recurrence could not said to be low in our combination therapy. It may be understood to be the reason for this improvement in relative long-term survival rate that the concurrent combination use of two treatment modalities resulted in an augmented carcinostatic effect on cancer cells, leading to a prolonged period to local recurrence and remote metastases. Also, it seems that the potentiated effect on cancer cells was not so perfectly lethal in the majority of cases but local recurrence and remote metastases occurred in the long clinical course and a permanent cure was hardly achieved. Therefore, it may be considered from our present study that the advantage of this combination therapy is to prolong the life of a cancer patient, and that the curativity of this therapy is largely limited, like that of radiation therapy alone.
The curable indications of this combination therapy will be summarized as follows. The absence of remote metastases was the pre-requisite for a cure. By the staging of cancer lesions, the Ti and T2 were good indications to get a cure, but because of extremely high incidence of local recurrence, there was hardly a chance of cure in the T3 cases. By cancer type, the ulcerous type, especially with a shallow and smoothly margined ulcer, was the good indication. No local cure could be expected in the funnelled type, so there was no possibility of longterm survival in this type. Local cure was most probable in the tumorous type, but a complete cure was not easy because of high incidence of remote metastases.
In the last place, the problems to improve this therapy will be discussed. Considering the adverse effects and the presence of complications, it will not be easy to increase either the dose of radiation or the dose of Bleomycin for the control of primary lesion, and we consider that a total tumor dose of 600 rad/6 weeks and a total dose of 100 mg of Bleomycin will be optimal. For the control of radioresistant cancer cells in primary lesion, the boost therapy with intracavitary radium application or high LET radiation will be recommended. For the prevention of remote metastases, the long-term administration of other anti-cancer agents and the introduction of immunotherapy may be considered. We have already initiated the trial by the latter therapeutic means and will be able to report the results in the near future.
